Abbott Laboratories Announces Strong Q1 2025 Financial Results

Abbott Laboratories has kicked off 2025 with impressive financial performance, reporting a 4% increase in revenue to $10.4 billion for the first quarter compared to the same period last year. The company's net earnings saw a significant 8.2% year-on-year growth, reaching $1.3 billion, with diluted earnings per share (EPS) up by 8.6% to $0.76.

CEO Robert Ford Highlights Diversified Business Model

"Once again, Abbott's diversified business model delivered top-tier sales and EPS growth. It is this diversification and execution that allows Abbott to navigate through periods of uncertainty and continually deliver sustainable growth," stated CEO Robert Ford. The company has reaffirmed its 2025 guidance, projecting organic sales growth of 7.5% to 8.5%, an adjusted operating margin between 23.5% and 24.0% of sales, and adjusted diluted EPS between $5.05 and $5.25.